Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK buying Sitari Pharmaceuticals
by Ryan Cross
September 14, 2019
| A version of this story appeared in
Volume 97, Issue 36
GlaxoSmithKline will acquire Sitari Pharmaceuticals for an undisclosed sum. GSK and venture capital firm Avalon Ventures founded Sitari in 2013. GSK and Avalon struck a deal at the time to fund up to 10 biotech start-ups at Avalon’s incubator, COI Pharmaceuticals, and have launched 8 start-ups so far. Sitari has focused on developing small-molecule inhibitors of transglutaminase 2, an enzyme that ignites inflammation in response to gluten in people with celiac disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter